Profile data is unavailable for this security.
About the company
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
- Revenue in USD (TTM)214.52m
- Net income in USD789.00k
- Incorporated1989
- Employees314.00
- LocationVericel Corp64 Sidney StCAMBRIDGE 02139United StatesUSA
- Phone+1 (734) 930-5555
- Fax+1 (734) 665-0485
- Websitehttps://vcel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tilray Brands Inc | 788.94m | -244.98m | 1.52bn | 2.65k | -- | 0.4301 | -- | 1.93 | -0.3334 | -0.3334 | 1.06 | 4.14 | 0.185 | 2.50 | 8.40 | 297,714.00 | -5.22 | -- | -5.72 | -- | 28.31 | -- | -28.19 | -- | 1.42 | -0.9071 | 0.0963 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Harrow Inc | 154.15m | -33.58m | 1.65bn | 315.00 | -- | 28.17 | -- | 10.70 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.71bn | 497.00 | -- | -- | -- | 6.08 | -1.07 | -1.07 | 5.55 | -- | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Supernus Pharmaceuticals Inc | 630.16m | 5.24m | 1.77bn | 652.00 | 363.75 | 1.85 | 19.62 | 2.81 | 0.0883 | 0.0883 | 11.39 | 17.39 | 0.4831 | 0.9256 | 4.36 | 966,507.70 | 0.4016 | 4.95 | 0.5117 | 6.41 | 88.34 | 88.61 | 0.8314 | 12.84 | 1.69 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 1.92bn | 58.00 | 47.20 | 2.45 | 24.82 | 14.37 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Endo Inc | -100.00bn | -100.00bn | 2.02bn | 3.00k | -- | 1.10 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 656.11m | 114.99m | 2.22bn | 246.00 | 19.96 | 4.11 | 15.90 | 3.38 | 1.95 | 1.95 | 11.19 | 9.48 | 0.8107 | 25.74 | 8.93 | 2,667,110.00 | 14.21 | 7.46 | 16.68 | 9.08 | 79.41 | 80.58 | 17.53 | 10.46 | 3.09 | 52.20 | 0.2571 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Vericel Corp | 214.52m | 789.00k | 2.35bn | 314.00 | 2,539.93 | 9.66 | 396.58 | 10.98 | 0.0189 | 0.0189 | 4.46 | 4.97 | 0.624 | 4.41 | 4.97 | 683,184.70 | 0.2295 | -3.07 | 0.2595 | -3.50 | 70.42 | 67.87 | 0.3678 | -4.49 | 4.16 | -- | 0.0008 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.44bn | 1.76k | 15.96 | 3.44 | 11.10 | 3.42 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Catalyst Pharmaceuticals Inc | 434.48m | 68.15m | 2.53bn | 167.00 | 40.02 | 4.16 | 24.20 | 5.83 | 0.5335 | 0.5335 | 3.71 | 5.14 | 0.7554 | 4.03 | 8.69 | 2,601,647.00 | 11.85 | 25.42 | 13.56 | 29.81 | 86.67 | 85.63 | 15.69 | 30.87 | 4.94 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.73bn | 7.70k | -- | -- | 29.63 | 1.05 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Twist Bioscience Corp | 295.21m | -220.31m | 2.81bn | 919.00 | -- | 5.72 | -- | 9.52 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
Data as of Sep 20 2024. Currency figures normalised to Vericel Corp's reporting currency: US Dollar USD
54.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 7.35m | 14.99% |
| Brown Capital Management LLCas of 30 Jun 2024 | 4.42m | 9.01% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.31m | 6.75% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.48m | 5.07% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.33m | 4.74% |
| Conestoga Capital Advisors LLCas of 30 Jun 2024 | 2.04m | 4.16% |
| Invesco Advisers, Inc.as of 30 Jun 2024 | 1.44m | 2.94% |
| GW&K Investment Management LLCas of 30 Jun 2024 | 1.26m | 2.56% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.14m | 2.33% |
| New York State Common Retirement Fundas of 30 Jun 2024 | 1.09m | 2.23% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
